Anticipation Builds For Rain Oncology's Phase 3 MANTRA Trial Results, Analyst Sees Promise
Anticipation Builds For Rain Oncology's Phase 3 MANTRA Trial Results, Analyst Sees Promise
分析師認爲前景看好，人們對Rain Oncology的3期MANTRA試驗結果寄予厚望
- In early March, in its Q4 earnings release, Rain Oncology Inc (NASDAQ:RAIN) announced that the topline data from its Phase 3 (MANTRA) trial of milademetan (MDM2 inhibitor) vs. Yondelis (trabectedin) in liposarcoma would be delayed by a quarter, with a primary endpoint (progression-free survival, or PFS) readout now slated to occur imminently this quarter.
- Earlier data readout was expected in Q1 of 2023.
- HC Wainwright says this is favorable, as the delay in reaching the required number (105) of PFS events could indicate that the active arm performed well. The analyst reiterates the Buy rating with a price target of $19.
- The analyst estimates about three months of PFS for the control arm.
- The MANTRA trial finished enrolling 175 patients in July 2022, and in its Q1 earnings release, it announced that the required number of PFS events has been reached. PFS data release in 2Q23 suggests at least eight months between the last patient enrolled and the readout.
- The analyst notes that milademetan previously achieved a 7.4- month PFS duration in a Phase 1 trial in liposarcoma patients, more than double the PFS rate for standard-of-care therapies, providing another reason to expect positive results.
- Assuming positive data from the MANTRA trial, the competition might need to improve upon the benchmark set by Rain Oncology, writes the analyst.
- Rain had $109.8 million in cash, cash equivalents, and short-term investments in Q1. But the company did not provide guidance on the cash runway. It is assessing its cash runway and might provide some update after the MANTRA topline results.
- Price Action: RAIN shares are down 5.28% at $8.79 on the last check Friday.
- In early March, in its Q4 earnings release, Rain Oncology Inc (NASDAQ:RAIN) announced that the topline data from its Phase 3 (MANTRA) trial of milademetan (MDM2 inhibitor) vs. Yondelis (trabectedin) in liposarcoma would be delayed by a quarter, with a primary endpoint (progression-free survival, or PFS) readout now slated to occur imminently this quarter.
- Earlier data readout was expected in Q1 of 2023.
- HC Wainwright says this is favorable, as the delay in reaching the required number (105) of PFS events could indicate that the active arm performed well. The analyst reiterates the Buy rating with a price target of $19.
- The analyst estimates about three months of PFS for the control arm.
- The MANTRA trial finished enrolling 175 patients in July 2022, and in its Q1 earnings release, it announced that the required number of PFS events has been reached. PFS data release in 2Q23 suggests at least eight months between the last patient enrolled and the readout.
- The analyst notes that milademetan previously achieved a 7.4- month PFS duration in a Phase 1 trial in liposarcoma patients, more than double the PFS rate for standard-of-care therapies, providing another reason to expect positive results.
- Assuming positive data from the MANTRA trial, the competition might need to improve upon the benchmark set by Rain Oncology, writes the analyst.
- Rain had $109.8 million in cash, cash equivalents, and short-term investments in Q1. But the company did not provide guidance on the cash runway. It is assessing its cash runway and might provide some update after the MANTRA topline results.
- Price Action: RAIN shares are down 5.28% at $8.79 on the last check Friday.
- 3月初，在發佈的第四季度財報中， Rain Onco 納斯達克股票代碼：RAIN）宣佈，其在脂肪肉瘤中米拉美坦（MDM2抑制劑）對比Yondelis（trabectedin）的3期（MANTRA）試驗的頭條數據將推遲四分之一，主要終點（無進展存活率或PFS）的讀數現定於本季度即將公佈。
- 較早的數據預計將在2023年第一季度公佈。
- HC Wainwright說，這是有利的，因爲延遲達到所需的PFS事件數量（105）可能表明活躍手臂表現良好。分析師重申買入評級，目標股價爲19美元。
- 分析師估計，控制部門大約需要三個月的PFS。
- MANTRA 試驗於 2022 年 7 月完成了 175 名患者的入組，並在其第一季度財報中宣佈已達到所需的 PFS 事件數量。23年第二季度發佈的PFS數據表明，從最後一次入組患者到讀出至少有八個月的時間。
- 這位分析師指出，milademetan此前在一項針對脂肪肉瘤患者的1期試驗中實現了7.4個月的PFS持續時間，是標準治療療法的PFS率的兩倍多，這爲預期取得積極結果提供了另一個理由。
- 這位分析師寫道，假設MANTRA試驗得出了積極的數據，那麼競爭對手可能需要改進Rain Oncology設定的基準。
- Rain在第一季度擁有1.098億美元的現金、現金等價物和短期投資。但是該公司沒有提供有關現金流的指導。它正在評估其現金流，並可能在MANTRA的頭條業績公佈後提供一些最新情況。
- 價格走勢： 在週五的最後一張支票中，RAIN股價下跌5.28％，至8.79美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！